Market Overview

Why Lannett Shares Are Down More Than 16%

Related LCI
Pharma Pair Trade? Susquehanna Starts Lannet At Buy, Akorn At Neutral
Analyst Knocks High-Profile Biotech Merger Battle; Opportunities Elsewhere

Shares of Lannett (NYSE: LCI) are down more than 16 percent following a research note from Roth Capital.

Generic drugmaker Impax Laboratories (NASDAQ: IPXL) has come under fire for price fixing of Digoxin, a drug that Lannett also produces. According to the Roth Capital note, Lannett may also get a subpoena. This would be very damaging for the stock, as Digoxin makes up approximately 23 percent of sales.

Related Link: Exclusive: Bio-Techne Executive On M&A Possibilities

The Roth note also commented that the generic drug space may not be sustainable in the long run.

These comments come despite Roth’s Buy rating and $45 price target. Shares of Lannett were last down 16.5 percent to $39.30.

Latest Ratings for LCI

Jul 2015SusquehannaInitiates Coverage onPositive
Jul 2015SusquehannaInitiates Coverage onPositive
Jun 2015Raymond JamesInitiates Coverage onOutperform

View More Analyst Ratings for LCI
View the Latest Analyst Ratings

Posted-In: Roth CapitalAnalyst Color Analyst Ratings


Related Articles (LCI + IPXL)

Get Benzinga's Newsletters